Home » Posts tagged with » myelodysplastic syndromes
Curis doses first patient in CA-4948 phase 1 clinical trial in AML and MDS

Curis doses first patient in CA-4948 phase 1 clinical trial in AML and MDS

CA-4948 phase 1 clinical trial : US biotech company Curis said that it has dosed the first patient with CA-4948 in a phase 1 clinical trial that is evaluating the small molecule IRAK4 kinase inhibitor for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The phase 1 clinical trial for CA-4948 will […]

EC approves Reblozyl for transfusion-dependent anemia in adults

Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the treatment of transfusion-dependent anemia in adult patients. The approval of Reblozyl is for transfusion-dependent anemia caused by very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had […]

Continue reading …